Rajiv Patni

CIK 1616200 · Chief Medical Officer · last filed 2026-09-10

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

-$64.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ADMS price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O BIOXCEL THERAPEUTICS, INC.
555 LONG WHARF DRIVE
NEW HAVEN, CT 06511

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
SEPN	Chief Medical Officer	—	$41.12	—	$0	1	2026-09-10
BioXcel Therapeutics, Inc. (BTAI) Delisted	Director	—	$0.07	—	$0	2	2026-01-12
QNCX	Director	—	$31.73	—	$0	3	2025-06-06
REATA PHARMACEUTICALS INC (RETA) Delisted	EVP, Chief R&D Officer	0	$172.36	$0	$0	2	2023-09-26
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted	EVP, CMO	35,000	—	—	$0	2	2020-07-02
Adamas Pharmaceuticals Inc (ADMS) Delisted	Chief Medical Officer	49,141	$8.22	$403.9K	-$64.0K	8	2019-04-10

Recent Filings · Page 2 of 2

20 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2019-04-10	Adamas Pharmaceuticals Inc (ADMS) Delisted	Grant (A)	+30,000	$0	EDGAR
2019-03-21	Adamas Pharmaceuticals Inc (ADMS) Delisted	Sell (S)	−2,374	-$19.0K	EDGAR
2018-03-22	Adamas Pharmaceuticals Inc (ADMS) Delisted	Sell (S)	−1,252	-$32.5K	EDGAR
2018-03-09	Adamas Pharmaceuticals Inc (ADMS) Delisted	Grant (A)	+9,125	$0	EDGAR
2017-03-22	Adamas Pharmaceuticals Inc (ADMS) Delisted	Sell (S)	−733	-$12.5K	EDGAR
2017-01-20	Adamas Pharmaceuticals Inc (ADMS) Delisted	Grant (A)	+6,875	$0	EDGAR
2016-03-08	Adamas Pharmaceuticals Inc (ADMS) Delisted	Grant (A)	+7,500	$102.5K	EDGAR
2015-06-09	Adamas Pharmaceuticals Inc (ADMS) Delisted	Grant (A)	—	$0	EDGAR
2015-05-07	—	Buy (P)	+5,050	$20.0K
2014-09-02	—	Grant (A)	—	$0

Showing 11–20 of 20

Prev Page 2 of 2

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.